Prostate cancer (PCa) is a highly common cancer among men but lacks robust diagnostics
that can predict disease recurrence after initial treatment, for example, with radical …

BACKGROUND: Prostate cancer (PCa) is a clinically and pathologically heterogeneous
disease. The rapid development of sequencing technology has the potential to deliver new …

Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …

Prostate cancer (PC) is one of the most common cancers among men worldwide, and
advanced PCs, such as locally advanced PC (LAPC) and castration-resistant PC (CRPC) …

Background: Compared to non-recurrent type, recurrent prostate adenocarcinoma (PCa) is
highly fatal, and significantly shortens the survival time of affected patients. Early and …

Prostate cancer is a highly heterogeneous disease and the second more common tumor in
males. Molecular and genetic profiles are currently used to identify subtypes and to guide …

Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …

Prostate cancer is a leading cause of cancer-related death in Western men. Our
understanding of the genetic alterations associated with disease predisposition …

Prostate cancer is the most common form of non-dermatological cancer among US men,
with an increasing incidence due to the aging population. Patients diagnosed with clinically …

Prostate cancer (PCa) is a heterogeneous disease with highly variable clinical outcomes
which presents enormous challenges in the clinical management. A vast amount of …